Press Release

Sal. Oppenheim is designated sponsor of MOLOGEN shares

Berlin, 2005-01-21

Sal. Oppenheim is designated sponsor of MOLOGEN shares

MOLOGEN AG, Berlin, and Bankhaus Sal. Oppenheim jr. & Cie. KgaA, Frankfurt am Main, have agreed that Sal. Oppenheim as of today will perform the Designated Sponsoring for MOLOGEN shares. During the daily trading hours set by Deutsche Boerse AG, Sal. Oppenheim will provide ask and bid quotes within the electronic trading system XETRA®. The objective is to substantially increase the trading and the liquidity of the share and to reduce transaction costs for shareholders. MOLOGEN is pleased to have won with Sal. Oppenheim one of the most renowned partners for designated sponsoring.


Additional information on Designated Sponsoring and XETRA® can be found on the homepage of Deutsche Boerse AG (

Link: Deutsche Börse - Designated Sponsoring

Link: Deutsche Börse - XETRA®



MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focus are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded at Geregelter Markt, Frankfurt Stock Exchange.


Contact: Matthias Reichel
Phone: +49-30-84 17 88 - 0
Fax: +49-30-84 17 88 - 50
e-mail: [email protected]